News und Analysen

Are Pfizer's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its recent stint of unprofitability and a

Are Pfizer's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its recent stint of unprofitability and a

Few industries are more essential than healthcare. That makes it an excellent place to look for stocks that can perform well over extended periods since the basic services they offer are unlikely to

Novavax (NASDAQ: NVAX) stock is suddenly a buy again this year, with its stock price more than tripling since the start of 2024. Some positive developments in recent months, including a deal with

We're almost halfway through the year, and so far, it's been a pretty solid one for equity markets. It's as good a time as any to review one's portfolio and potentially consider putting more money

We're almost halfway through the year, and so far, it's been a pretty solid one for equity markets. It's as good a time as any to review one's portfolio and potentially consider putting more money

We're almost halfway through the year, and so far, it's been a pretty solid one for equity markets. It's as good a time as any to review one's portfolio and potentially consider putting more money

Shares of Axsome Therapeutics (NASDAQ: AXSM) were sinking 6.8% lower as of 11:19 a.m. ET on Tuesday. The decline came after Culper Research announced a short position in the biotech stock before the

Johnson & Johnson reigned as the largest healthcare company in the world for years. UnitedHealth Group also took a turn at the top. However, the title now belongs to Eli Lilly (NYSE: LLY) -- and it

Johnson & Johnson reigned as the largest healthcare company in the world for years. UnitedHealth Group also took a turn at the top. However, the title now belongs to Eli Lilly (NYSE: LLY) -- and it

Billionaire investors generally don't necessarily need dividend income to make ends meet. They buy dividend-paying stocks because they know that companies committed to returning a portion of

Billionaire investors generally don't necessarily need dividend income to make ends meet. They buy dividend-paying stocks because they know that companies committed to returning a portion of

Viking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent biotech companies that have a lot in common. Both focus on treating metabolic illnesses like liver

The biotech industry features many prominent companies that command plenty of attention on the market. And since the year started, few biotechs have made more noise than Viking Therapeutics (NASDAQ:

Healthcare giants sometimes pay decent dividend distributions, and UnitedHealth Group (NYSE: UNH) certainly falls into that category. In the wake of difficult circumstances, however, investors might

Healthcare giants sometimes pay decent dividend distributions, and UnitedHealth Group (NYSE: UNH) certainly falls into that category. In the wake of difficult circumstances, however, investors might

Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer

Generating dividend income can be an excellent way to put your cash to work. It can provide you with an extra stream of cash flow to diversify your income and help you pay bills, or perhaps fund a

Generating dividend income can be an excellent way to put your cash to work. It can provide you with an extra stream of cash flow to diversify your income and help you pay bills, or perhaps fund a

On June 2, Intellia Therapeutics' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words

Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper.

Three Motley Fool